OBJECTIVE：To analyze the cost-effectiveness of two regimens in the treatment of chronic hepatitis B fibrosis. METHODS：112 cases of chronic hepatitis B fibrosis were divided into Compound biejia ruangan tablet group（group A，n＝56） and Anluo huaxian pill group（group B，n＝56）. Both groups received Entecavir dispersible tablets combined with relevant Chinese patent medicine. The liver fibrosis index and transient elastography of 2 group were detected before and after treatment，TCM symptom score and effective rate calculation were conducted to compare the cost-effectiveness of 2 groups. RESULTS：The cost，effective rate and cost-effectiveness ratio of group A were 9 227.10 yuan，74.11％ and 12 451；those of group B were 8 202.90 yuan， 69.28％ and 11 840；incremental cost-effectiveness ratio was 21 205. Group B showed a better cost-effectiveness. Result of sensitivity test was same to that of cost-effectiveness analysis. CONCLUSIONS：The cost-effectiveness of Anluo huaxian pill combined with Entecavir dispersible tables is better than Compound biejia ruangan tablet combined with Entecavir dispersible tables in the treatment of chronic hepatitis B fibrosis.